Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences

Conway, 2014, The polycystic ovary syndrome: a position statement from the European Society of Endocrinology, Eur J Endocrinol, 171, P1, 10.1530/EJE-14-0253 Legro, 2013, Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab, 98, 4565, 10.1210/jc.2013-2350 Lujan, 2008, Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies, J Obstet Gynaecol Can, 30, 671, 10.1016/S1701-2163(16)32915-2 Johnstone, 2010, The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance, J Clin Endocrinol Metab, 95, 4965, 10.1210/jc.2010-0202 Dewailly, 2014, Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society, Hum Reprod Update, 20, 334, 10.1093/humupd/dmt061 Azziz, 2009, The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report, Fertil Steril, 91, 456, 10.1016/j.fertnstert.2008.06.035 March, 2010, The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria, Hum Reprod, 25, 544, 10.1093/humrep/dep399 Goodarzi, 2011, Polycystic ovary syndrome: etiology, pathogenesis and diagnosis, Nat Rev Endocrinol, 7, 219, 10.1038/nrendo.2010.217 Sir-Petermann, 2005, Birth weight in offspring of mothers with polycystic ovarian syndrome, Hum Reprod, 20, 2122, 10.1093/humrep/dei009 Paschou, 2015, Birth weight and polycystic ovary syndrome in adult life: is there a causal link?, PLoS One, 10, e0122050, 10.1371/journal.pone.0122050 Zhao, 2016, Genetic studies on polycystic ovary syndrome, Best Pract Res Clin Obstet Gynaecol, 37, 56, 10.1016/j.bpobgyn.2016.04.002 Randeva, 2012, Cardiometabolic aspects of the polycystic ovary syndrome, Endocr Rev, 33, 812, 10.1210/er.2012-1003 Cassar, 2016, Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies, Hum Reprod, 31, 2619, 10.1093/humrep/dew243 Engmann, 2017, Reproductive Medicine Network. Racial and ethnic differences in the polycystic ovary syndrome metabolic phenotype, Am J Obstet Gynecol, 216, 493.e1, 10.1016/j.ajog.2017.01.003 Diamanti-Kandarakis, 2007, Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS, Clin Endocrinol (Oxf), 67, 735, 10.1111/j.1365-2265.2007.02954.x Panidis, 2012, Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study, Hum Reprod, 27, 541, 10.1093/humrep/der418 Paschou, 2017, Adrenal hyperandrogenism does not deteriorate insulin resistance and lipid profile in women with PCOS, Endocr Connect, 6, 601, 10.1530/EC-17-0239 Diamanti-Kandarakis, 2012, Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications, Endocr Rev, 33, 981, 10.1210/er.2011-1034 Legro, 1999, Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women, J Clin Endocrinol Metab, 84, 165 Gambineri, 2012, Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study, Diabetes, 61, 2369, 10.2337/db11-1360 Moran, 2010, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update, 16, 347, 10.1093/humupd/dmq001 Livadas, 2017, Letter to the Editor: Development and risk factors of type 2 diabetes in a nation-wide population of women with polycystic ovary syndrome, J Clin Endocrinol Metab. Yu, 2016, Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis, Medicine (Baltimore), 95, e4863, 10.1097/MD.0000000000004863 Flannery, 2013, Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI, Pediatr Diabetes, 14, 42, 10.1111/j.1399-5448.2012.00902.x Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil Steril, 81, 19, 10.1016/j.fertnstert.2003.10.004 Legro, 2001, Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome, Am J Med, 111, 607, 10.1016/S0002-9343(01)00948-2 Wild, 1985, Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 61, 946, 10.1210/jcem-61-5-946 Yilmaz, 2005, Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome, Gynecol Endocrinol, 20, 258, 10.1080/09513590400027265 Pirwany, 2001, Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters, Clin Endocrinol (Oxf), 54, 447, 10.1046/j.1365-2265.2001.01228.x Macut, 2006, Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS, Eur J Endocrinol, 155, 131, 10.1530/eje.1.02187 Savage, 2007, Disordered lipid metabolism and the pathogenesis of insulin resistance, Physiol Rev, 87, 507, 10.1152/physrev.00024.2006 Wild, 2011, Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis, Fertil Steril, 95, 10.1016/j.fertnstert.2010.12.027 Berneis, 2009, Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome, Int J Clin Pract, 63, 56, 10.1111/j.1742-1241.2008.01897.x Essah, 2008, Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome, J Endocrinol Invest, 31, 35, 10.1007/BF03345564 Graf, 1990, The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women, Clin Endocrinol (Oxf), 33, 119, 10.1111/j.1365-2265.1990.tb00472.x Yusuf, 2004, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9 Savva, 2013, Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis, Diabetes Metab Syndr Obes, 6, 403, 10.2147/DMSO.S34220 Sam, 2007, Obesity and polycystic ovary syndrome, Obes Manag, 3, 69, 10.1089/obe.2007.0019 Lim, 2012, Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update, 18, 618, 10.1093/humupd/dms030 Horejsi, 2004, Android subcutaneous adipose tissue topography in lean and obese women suffering from PCOS: comparison with type 2 diabetic women, Am J Phys Anthropol, 124, 275, 10.1002/ajpa.10364 Tafeit, 2003, Subcutaneous adipose tissue pattern in lean and obese women with polycystic ovary syndrome, Exp Biol Med (Maywood), 228, 710, 10.1177/153537020322800610 Alvarez-Blasco, 2006, Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women, Arch Intern Med, 166, 2081, 10.1001/archinte.166.19.2081 Anagnostis, 2012, Metabolic syndrome in the Mediterranean region: current status, Indian J Endocrinol Metab, 16, 72, 10.4103/2230-8210.91195 Athyros, 2010, Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population, Curr Med Res Opin, 26, 713, 10.1185/03007991003590597 Essah, 2006, The metabolic syndrome in polycystic ovary syndrome, J Endocrinol Invest, 29, 270, 10.1007/BF03345554 Glueck, 2003, Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome, Metabolism, 52, 908, 10.1016/S0026-0495(03)00104-5 Vryonidou, 2015, Mechanisms in endocrinology: metabolic syndrome through the female life cycle, Eur J Endocrinol, 173, R153, 10.1530/EJE-15-0275 Espinós-Gómez, 2012, Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset, Gynecol Endocrinol, 28, 264, 10.3109/09513590.2011.613968 Panidis, 2013, Prevalence of metabolic syndrome in women with polycystic ovary syndrome, Clin Endocrinol (Oxf), 78, 586, 10.1111/cen.12008 Orio, 2003, Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome, J Clin Endocrinol Metab, 88, 5887, 10.1210/jc.2002-021816 Hirschberg, 2004, Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome, Gynecol Endocrinol, 19, 79, 10.1080/09513590400002300 Naessén, 2006, Polycystic ovary syndrome in bulimic women–an evaluation based on the new diagnostic criteria, Gynecol Endocrinol, 22, 388, 10.1080/09513590600847421 Moran, 2004, Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition, J Clin Endocrinol Metab, 89, 3337, 10.1210/jc.2003-031583 Goverde, 2009, Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria, Hum Reprod, 24, 710, 10.1093/humrep/den433 Zhang, 2009, Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population, BJOG, 116, 1633, 10.1111/j.1471-0528.2009.02347.x Lumeng, 2011, Inflammatory links between obesity and metabolic disease, J Clin Invest, 121, 2111, 10.1172/JCI57132 Gonzalez, 1999, Elevated serum levels of tumor necrosis factor in normal-weight women with polycystic ovary syndrome, Metabolism, 48, 437, 10.1016/S0026-0495(99)90100-2 Bañuls, 2017, Metabolic syndrome enhances endoplasmic reticulum, oxidative stress and leukocyte-endothelium interactions in PCOS, Metabolism, 71, 153, 10.1016/j.metabol.2017.02.012 Escobar-Morreale, 2004, Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity, J Clin Endocrinol Metab, 89, 806, 10.1210/jc.2003-031365 Shroff, 2007, Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis, J Clin Endocrinol Metab, 92, 4609, 10.1210/jc.2007-1343 Eser, 2017, The effects of IL-1A and IL-6 genes polymorphisms on gene expressions, hormonal and biochemical parameters in polycystic ovary syndrome, J Obstet Gynaecol, 37, 358, 10.1080/01443615.2016.1256966 Boulman, 2004, Blumenfeld Z' Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease, J Clin Endocrinol Metab, 89, 2160, 10.1210/jc.2003-031096 Ridker, 2000, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med, 342, 836, 10.1056/NEJM200003233421202 Spritzer, 2015, Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome, Reproduction, 149, R219, 10.1530/REP-14-0435 Athyros, 2010, Should adipokines be considered in the choice of the treatment of obesity-related health problems?, Curr Drug Targets, 11, 122, 10.2174/138945010790030992 Toulis, 2009, Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis, Hum Reprod Update, 15, 297, 10.1093/humupd/dmp006 Gao, 2012, Association of the T45G and G276T polymorphisms in the adiponectin gene with PCOS: a meta-analysis, Gynecol Endocrinol, 28, 106, 10.3109/09513590.2010.508543 Zheng, 2017, Leptin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis, Reprod Sci, 24, 656, 10.1177/1933719116670265 Veldhuis, 2001, Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome, J Clin Endocrinol Metab, 86, 3772, 10.1210/jcem.86.8.7775 Dambala, 2017, Serum visfatin, vascular endothelial growth factor and matrix metalloproteinase-9 in women with polycystic ovary syndrome, Gynecol Endocrinol, 1 Sun, 2015, High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis, Gynecol Endocrinol, 31, 808, 10.3109/09513590.2015.1056140 Tang, 2017, Circulating omentin-1 levels in women with polycystic ovary syndrome: a meta-analysis, Gynecol Endocrinol, 33, 244, 10.1080/09513590.2016.1254180 Polyzos, 2016, Nonalcoholic fatty future disease, Metabolism, 65, 1007, 10.1016/j.metabol.2015.12.009 Gutierrez-Grobe, 2010, Prevalence of non-alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens, Ann Hepatol, 9, 402, 10.1016/S1665-2681(19)31616-3 Brzozowska, 2009, An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome, J Gastroenterol Hepatol, 24, 243, 10.1111/j.1440-1746.2008.05740.x Macut, 2016, Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome, Hum Reprod, 31, 1347, 10.1093/humrep/dew076 Rocha, 2017, Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis, J Endocrinol Invest, 10.1007/s40618-017-0708-9 Jones, 2012, Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance, J Clin Endocrinol Metab, 97, 3709, 10.1210/jc.2012-1382 Hossain, 2011, Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS), Scand J Gastroenterol, 46, 479, 10.3109/00365521.2010.539251 Shi, 2014, Hypertension in women with polycystic ovary syndrome: prevalence and associated cardiovascular risk factors, Eur J Obstet Gynecol Reprod Biol, 173, 66, 10.1016/j.ejogrb.2013.11.011 Elting, 2001, Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population, Hum Reprod, 16, 556, 10.1093/humrep/16.3.556 Orbetzova, 2003, Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome, Folia Med (Plovdiv), 45, 21 Holte, 1996, Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?, Hum Reprod, 11, 23, 10.1093/oxfordjournals.humrep.a019028 Zimmermann, 1992, Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance, J Clin Endocrinol Metab, 75, 508 Schmidt, 2011, Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study, J Clin Endocrinol Metab, 96, 3794, 10.1210/jc.2011-1677 Cascella, 2006, Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome, J Clin Endocrinol Metab, 91, 4395, 10.1210/jc.2006-0399 Pinola, 2017, Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life, Fertil Steril, 107, 788, 10.1016/j.fertnstert.2016.12.017 Mannerås-Holm, 2011, Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 96, 1068, 10.1210/jc.2010-2279 Yildiz, 2002, Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state, J Clin Endocrinol Metab, 87, 3871, 10.1210/jcem.87.8.8716 Atiomo, 2000, Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS), Clin Endocrinol (Oxf), 52, 487, 10.1046/j.1365-2265.2000.00946.x Atiomo, 2000, Are women with polycystic ovary syndrome resistant to activated protein C?, Fertil Steril, 74, 1229, 10.1016/S0015-0282(00)01614-9 Tsanadis, 2002, Polycystic ovarian syndrome and thrombophilia, Hum Reprod, 17, 314, 10.1093/humrep/17.2.314 Schachter, 2003, Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine, Hum Reprod, 18, 721, 10.1093/humrep/deg190 Domecq, 2013, Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis, J Clin Endocrinol Metab, 98, 4646, 10.1210/jc.2013-2374 Yildiz, 2015, Approach to the patient: contraception in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 100, 794, 10.1210/jc.2014-3196 Yousuf, 2017, Does the oral contraceptive pill increase plasma intercellular adhesion molecule-1, monocyte chemoattractant protein-1, and tumor necrosis factor-α levels in women with polycystic ovary syndrome: a pilot study, J Pediatr Adolesc Gynecol, 30, 58, 10.1016/j.jpag.2016.06.010 Lidegaard, 2011, Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9, BMJ, 343, d6423, 10.1136/bmj.d6423 McFarlane, 2001, Insulin resistance and cardiovascular disease, J Clin Endocrinol Metab, 86, 713 Wormser, 2011, Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies, Lancet, 377, 1085, 10.1016/S0140-6736(11)60105-0 Talbott, 2004, Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome, J Clin Endocrinol Metab, 89, 5454, 10.1210/jc.2003-032237 Carmina, 2006, Endothelial dysfunction in PCOS: role of obesity and adipose hormones, Am J Med, 119, 356.e1, 10.1016/j.amjmed.2005.10.059 Vryonidou, 2005, Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 2740, 10.1210/jc.2004-2363 Kravariti, 2005, Predictors of endothelial dysfunction in young women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 5088, 10.1210/jc.2005-0151 Armeni, 2013, Arterial stiffness is increased in asymptomatic nondiabetic postmenopausal women with a polycystic ovary syndrome phenotype, J Hypertens, 31, 1998, 10.1097/HJH.0b013e3283630362 Meyer, 2012, Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis, Hum Reprod Update, 18, 112, 10.1093/humupd/dmr046 Sprung, 2013, Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies, Clin Endocrinol (Oxf), 78, 438, 10.1111/j.1365-2265.2012.04490.x Okoroh, 2015, Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome, Thromb Res, 136, 1165, 10.1016/j.thromres.2015.10.022 Hart, 2015, The potential implications of a PCOS diagnosis on a woman's long-term health using data linkage, J Clin Endocrinol Metab, 100, 911, 10.1210/jc.2014-3886 Pierpoint, 1998, Mortality of women with polycystic ovary syndrome at long-term follow-up, J Clin Epidemiol, 51, 581, 10.1016/S0895-4356(98)00035-3 Wild, 2000, Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study, Clin Endocrinol (Oxf), 52, 595, 10.1046/j.1365-2265.2000.01000.x Iftikhar, 2012, Risk of cardiovascular events in patients with polycystic ovary syndrome, Neth J Med, 70, 74 Mani, 2013, Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study, Clin Endocrinol (Oxf), 78, 926, 10.1111/cen.12068 Merz, 2016, Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome, J Womens Health (Larchmt), 25, 875, 10.1089/jwh.2015.5441 Wang, 2011, Menstrual irregularity and cardiovascular mortality, J Clin Endocrinol Metab, 96, E114, 10.1210/jc.2010-1709 Solomon, 2002, Menstrual cycle irregularity and risk for future cardiovascular disease, J Clin Endocrinol Metab, 87, 2013, 10.1210/jcem.87.5.8471 de Groot, 2011, PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis, Hum Reprod Update, 17, 495, 10.1093/humupd/dmr001 Zhao, 2016, Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis, Oncotarget, 7, 33715, 10.18632/oncotarget.9553